Obseva (NASDAQ:OBSV) announced its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04, Morningstar.com reports.
Shares of Obseva stock traded down $0.57 on Friday, reaching $15.35. 26,596 shares of the company were exchanged, compared to its average volume of 137,080. The stock has a market capitalization of $584.80 million, a price-to-earnings ratio of -6.82 and a beta of 1.75. Obseva has a 1-year low of $9.05 and a 1-year high of $20.35.
A number of brokerages have recently weighed in on OBSV. Zacks Investment Research upgraded Obseva from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Thursday, October 18th. HC Wainwright set a $44.00 price target on Obseva and gave the stock a “buy” rating in a research report on Monday, October 15th. TheStreet upgraded Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. Wedbush set a $34.00 price target on Obseva and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Finally, JPMorgan Chase & Co. began coverage on Obseva in a research report on Thursday, September 13th. They set an “overweight” rating and a $29.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $29.43.
COPYRIGHT VIOLATION NOTICE: “Obseva (OBSV) Announces Quarterly Earnings Results” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/11/10/obseva-obsv-announces-quarterly-earnings-results/2973411.html.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.